1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,877 | 0,880 | 12:29 | |
| 0,877 | 0,880 | 12:29 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.04. | CARMAT Receives FDA Conditional Approval to Initiate the Second Cohort of the EFS Study in the United States | 200 | Business Wire | Recruitment of the second cohort expected to begin in H2 2025
Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming... ► Artikel lesen | |
| CARMAT Aktie jetzt für 0€ handeln | |||||
| 09.04. | CARMAT Delivers Q1 2025 Results in Line With Its Objectives | 205 | Business Wire | Quarterly sales of €2.4m multiplied by 2.4 vs Q1 2024
EFICAS clinical trial recruitment 94% complete
2 scientific publications a strong driver of Aeson® adoption
Final stage... ► Artikel lesen | |
| 03.04. | CARMAT - Publication in the JACC(1): Heart Failure of the Initial Clinical Experience with Aeson Total Artificial Heart in Cardiogenic Shock Patients Initially Placed on Extracorporeal Life Support | 233 | Business Wire | The retrospective analysis on 10 patients shows a 90% survival rate at 6 months, suggesting Aeson® as a therapeutic solution for these patients at risk of death in the short term.
Regulatory News:
CARMAT... ► Artikel lesen | |
| 31.03. | CARMAT to Provide a Business Update and Host a Videoconference on April 9, 2025 | 245 | Business Wire | Please register to the videoconference by clicking on one of the following links: Videoconference in French at 6:00 pm CEST -
Videoconference in English at 8:00 pm CEST
Regulatory News:
CARMAT... ► Artikel lesen | |
| 27.03. | CARMAT announces the implementation of a flexible equity financing line with IRIS Capital Investment | 338 | Business Wire | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
| 17.02. | CARMAT: Aeson total artificial heart highlighted as a very promising solution for heart failure patients with pulmonary hypertension in The Journal of Heart and Lung Transplantation | 442 | Business Wire | Up to 25% of advanced heart failure patients suffer from pulmonary hypertension
Aeson® could potentially become a standard treatment for these thousands of patients, both as a bridge-to-transplant... ► Artikel lesen | |
| 10.02. | CARMAT Achieves the Milestone of 100 Implants of Its Aeson Total Artificial Heart | 312 | Business Wire | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
| 31.01. | CARMAT Raises a Total of €9.7 Million | 612 | Business Wire | Regulatory News:
NOT FOR DIRECT OR INDIRECT DISTRIBUTION IN THE UNITED STATES OF AMERICA, SOUTH AFRICA, CANADA, AUSTRALIA OR JAPAN
CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), designer and developer... ► Artikel lesen | |
| 30.01. | CARMAT Launches a €10 Million Global Offering With €7 Million in Subscription Commitments | 566 | Business Wire | Global Offering composed of a reserved offering for qualified investors and a public offering for retail investors via the PrimaryBid platform
Issue price for new shares set at 0.77 euro... ► Artikel lesen | |
| 29.01. | CARMAT: 2025 Financial Calendar | 346 | Business Wire | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
| 13.01. | CARMAT Announces Its Participation in Several Scientific and Investor Conferences During the 1st Half of 2025 | 360 | Business Wire | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
| 08.01. | CARMAT Delivers a Solid FY 2024 with 42 Implants of Its Aeson Artificial Heart and Anticipates Continued Strong Momentum in 2025 | 343 | Business Wire | Over 90 patients have received the Aeson® artificial heart since the first implant in 2013, including 42 in 2024.
2024 Sales of €7 million (a 2.5-fold increase vs 2023).
Cash burn... ► Artikel lesen | |
| 23.12.24 | CARMAT optimizes its financial structure by buying-back, for a symbolic sum of one euro, 2 million shares from Matra-Défense (Airbus group) which will be allocated to the repayment of its financial debt | 532 | Business Wire | Buy-back by CARMAT of 2 million shares from Airbus for a symbolic sum of 1 euro. The shares so bought-back will be allocated to the repayment of the Company's financial debt, via their... ► Artikel lesen | |
| 26.11.24 | Successful first "Aeson European User Meeting", marking an important step in the deployment of CARMAT's artificial heart | 167 | Business Wire | More than 100 healthcare professionals from 41 hospitals and 10 countries rallied to share their experiences of the Aeson® artificial heart All hospitals taking part in the event confirmed... ► Artikel lesen | |
| 13.11.24 | CARMAT's Aeson Artificial Heart Is Gradually Becoming a Reference Solution for Bridge to Transplant in Europe | 682 | Business Wire | Milestone of 30 heart transplants post Aeson® support, passed Strong interest in Aeson® from the medical community: more than 100 European experts will share their experience at the first... ► Artikel lesen | |
| 30.09.24 | CARMAT Announces the Completion of Its Capital Increase for a Gross Amount of €10.3 Million (Namely 100% of the Initial Offer) | 531 | Business Wire | Continued and significant support from two reference shareholders, for a total amount of €5.5 million Net proceeds of €9.4 million, enabling CARMAT to extend its cash runway until early... ► Artikel lesen | |
| 18.09.24 | CARMAT Launches a Capital Increase for an Initial Amount of €10.3 Million to Finance Its Activities Until at Least the End of 2024 | 599 | Business Wire | This capital increase will be carried out through a public offering without preferential subscription rights and with a 7 trading days priority period, on an irreducible and reducible basis,... ► Artikel lesen | |
| 12.09.24 | Half of Enrolments Targeted in the EFICAS Study Reached by CARMAT | 462 | Business Wire | Enrolment expected to be completed in the first half of 2025
Publication of study results on 52 patients anticipated at the end 2025
Regulatory News:
CARMAT (FR0010907956, ALCAR)... ► Artikel lesen | |
| 06.09.24 | CARMAT Publishes Its 2024 Half-Year Results and Provides an Update on Its Outlook | 610 | Business Wire | Half-year sales of €3.3 million, exceeding 2023 full-year sales
20 implants of the Aeson® artificial heart performed in the first half of 2024
17% cash-burn1 reduction compared to... ► Artikel lesen | |
| 03.09.24 | CARMAT Announces Its Participation in Several Scientific and Investor Conferences during the 2nd Half of 2024 | 521 | Business Wire | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen |
Seite:
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 39,450 | -0,25 % | Mehr Geld für 21.000 Beschäftigte von Fresenius Helios | BERLIN/FRANKFURT (dpa-AFX) - Rund 21.000 Beschäftigte in den Helios-Kliniken des Gesundheitskonzerns Fresenius bekommen deutlich mehr Geld. Das Unternehmen hat sich mit der Gewerkschaft Verdi auf Lohnerhöhungen... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 42,100 | +0,05 % | BERNSTEIN RESEARCH stuft FMC FRESENIUS MEDICAL CARE AG & CO KGAA auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat die Einstufung für Fresenius Medical Care (FMC) auf "Market-Perform" mit einem Kursziel von 50 Euro belassen. Der Dialyseanbieter... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 45,670 | +1,99 % | UBS stuft Siemens Healthineers auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Siemens Healthineers mit einem Kursziel von 53 Euro auf "Neutral" belassen. Bei GE Healthcare, Philips und Siemens Healthineers... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 59,60 | +0,59 % | Carl Zeiss Meditec: Das war zu wenig … war aber auch nicht schlecht | Mit den gestern vorgelegten Vorab-Zahlen des Winterquartals hätte die Aktie des Medizintechnik-Unternehmens Carl Zeiss Meditec ein klar positives Signal im Chartbild hinterlassen können, wenn die Käufer... ► Artikel lesen | |
| ECKERT & ZIEGLER | 54,00 | +1,98 % | Eckert & Ziegler Aktie: Schacht Konrad belastet | Die Aktie von Eckert & Ziegler zeigt sich stabil, doch regulatorische Unsicherheiten um Schacht Konrad könnten den Strahlentechnik-Pionier herausfordern. Die Eckert & Ziegler-Aktie zeigt sich heute... ► Artikel lesen | |
| DRAEGERWERK | 59,80 | +2,57 % | Aixtron, Drägerwerk, Evotec, Kontron, Rheinmetall, Werder Bremen - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| MEDTRONIC | 73,62 | +0,88 % | Medtronic: Grammy Award Winning Artist Knows How Math Can Help Prevent Cancer | Anthony Hamilton experiences how Medtronic is using AI to help detect colon polyps NORTHAMPTON, MA / ACCESS Newswire / April 22, 2025 / Grammy Award winning singer and songwriter Anthony Hamilton underwent... ► Artikel lesen | |
| INTUITIVE SURGICAL | 421,00 | +0,43 % | Intuitive Surgical Inc. Q1 Profit Increases, Beats Estimates | SUNNYVALE (dpa-AFX) - Intuitive Surgical Inc. (ISRG) released a profit for its first quarter that increased from the same period last year and beat the Street estimates.The company's earnings... ► Artikel lesen | |
| GERRESHEIMER | 55,30 | +6,04 % | JEFFERIES stuft GERRESHEIMER AG auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat das Kursziel für Gerresheimer von 93 auf 86 Euro gesenkt, aber die Einstufung auf "Buy" belassen. Analyst James Vane-Tempest kappte am Mittwoch... ► Artikel lesen | |
| UNITEDHEALTH | 378,75 | +1,24 % | Dow Jones: UnitedHealth-Schock! | News von Trading-Treff.de Schwere Zeiten für den Dow Jones. Die Aktie der UnitedHealth Group (UNH) stürzt ab und zieht den gesamten Index mit nach unten. Am heutigen Donnerstag fiel der Index um 1,01... ► Artikel lesen | |
| TELADOC HEALTH | 6,297 | +4,15 % | Jefferies cuts Teladoc price target to $8, maintains hold rating | ||
| THERMO FISHER | 387,00 | +1,78 % | Thermo Fisher Scientific Q1 Profit Increases, Beats Estimates | WASHINGTON (dpa-AFX) - Thermo Fisher Scientific (TMO) reported earnings for its first quarter that increased from the same period last year and beat the Street estimates.The company's bottom... ► Artikel lesen | |
| STRATEC | 23,450 | +1,74 % | Stratec Biomedical Aktie: Analyse von Wachstumschancen | Der Diagnostik-Spezialist verzeichnet erhebliche Kursverluste, während Experten ein Wachstumspotenzial von über 80 Prozent prognostizieren. Wichtige Finanzdaten folgen Ende April. Die Aktie des Diagnostik-Spezialisten... ► Artikel lesen | |
| RHOEN-KLINIKUM | 15,500 | -2,52 % | Klinik für Kardiochirurgie erreicht Meilenstein: 500ste "Kunstherz"-Implantation am RHÖN-KLINIKUM Campus Bad Neustadt | Bad Neustadt a.d. Saale (ots) - Die Klinik für Kardiochirurgie am RHÖN-KLINIKUM Campus Bad Neustadt kann einen bedeutenden Meilenstein in der Behandlung von Herzinsuffizienz verzeichnen: Die Implantation... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 22,860 | 0,00 % | Privia Health Group, Inc.: Privia Health Reports Fourth Quarter and Full-Year 2024 Financial Results | All 2024 Operating and Financial Metrics Above High End of Guidance RangesVery strong New Provider Signings with Implemented Providers +11.2% from Year-end 2023Full-year 2024 Net Cash Provided by... ► Artikel lesen |
CARMAT gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell -0,23 % bei einem Aktienkurs von 0,884 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CARMAT finden Sie auf Wallstreet Online.
